ClinicalTrials.gg
CompletedNCT01118624Updated Jan 7, 2020Results posted

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

A Phase 2 interventional study of Pralatrexate Injection and Vitamin B12 in Breast Cancer, Breast Tumors and Neoplasms, Breast, sponsored by Acrotech Biopharma Inc.. Completed at 14 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,208 studies in Breast Neoplasms with a site in France — 207 open to participants now, 342 under way, 83 of them phase 3. Breast Neoplasms · France.

Enrollment
908th of 997
22 · median 150
Started
2010
with 43 others
Phase 2
247 of 1,208
26 open now
Registered
251st of 1,208
by date

Among the 1,208 studies in Breast Neoplasms with a site in France, this one is the 908th largest by enrollment of the 997 interventional ones that give a count, is one of 44 that started in 2010, is one of 247 in phase 2, and was the 251st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

207 of the 1,208 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

202 more — sign in →

All 207 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,208 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy (ability to provide a beneficial treatment of the disease) of pralatrexate for the treatment of female patients with advanced or metastatic breast cancer who have failed prior chemotherapy. Patients will receive vitamin B12 and folic acid supplementation.

Read the detailed description

This is an open label, multi-center, Phase 2 study of pralatrexate with vitamin B12 and folic acid supplementation in patients with advanced or metastatic breast cancer who have failed prior treatment(s).

The start of study treatment is defined as the initiation of pralatrexate administration.

Pralatrexate will be administered as an intravenous (IV) push over 3-5 minutes on days 1 and 15 (± 1 day at each time point) of a 4-week cycle (ie, every [q] 2 weeks). The initial dose of pralatrexate will be 190 mg/m2. Dose reduction to 150 mg/m2 with further reduction to 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity (see Section 7.3). If 100 mg/m2 is not tolerated, pralatrexate must be discontinued.

Patients will receive vitamin supplementation consisting of vitamin B12, 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1-1.25 mg by mouth (PO) once a day (QD). Patients must have received 1 mg vitamin B12 within 10 weeks prior to the initiation of pralatrexate and have received 7 days of 1-1.25 mg folic acid PO QD prior to the initiation of pralatrexate.

Vitamin supplementation will continue throughout the study and for at least 30 days after the last administration of pralatrexate.

03

Conditions studied

  • Breast Cancer
  • Breast Tumors
  • Neoplasms, Breast
  • Cancer of the Breast
  • Human Mammary Carcinoma

Keywords

  • Female
  • Advanced
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • negative advanced or breast cancer
  • Disease has become worse after at least 1 prior chemotherapy regimen for advanced or metastatic disease
  • Advanced or metastatic disease resistant to both a taxane and an anthracycline-containing chemotherapy regimen, or resistant to taxanes and for whom further anthracycline therapy is not indicated
  • Patients with controlled must have finished receiving radiation therapy and if on , be on a stable or tapering dose of ≤ 10 mg/day of prednisone or equivalent for at least 28 days prior to study entry
  • Female 18 years of age or older
  • Performance status less than or equal to 2
  • of more than 3 months
  • Blood, liver and kidney laboratory test results that meet protocol requirements
  • Patients must have a negative serum pregnancy test within 14 days before enrollment and agree to use medically acceptable and effective from enrollment until at least 30 days after the last dose of pralatrexate. Patients who are for at least 1 year (more than 12 months since last menses) or are surgically sterilized do not require this test.
  • Willing to attend visits for repeat dosing and follow up
  • Give written

Exclusion criteria

Exclusion Criteria:

  • Patients with only bone
  • Patients with a single metastatic site without histological proof that the lesion is metastatic breast cancer
  • Patients with inflammatory breast cancer
  • Treatment with systemic chemotherapy, hormone therapy, radiation therapy, or other therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C) prior to enrollment, except for the following:

    • Bisphosphonates, if ongoing
    • Prior treatment with methotrexate
    • Prior treatment with anti-angiogenics within 6 months prior to enrollment
  • Have received more than 2 prior chemotherapy regimens (more than 3 if one of the treatments was or adjuvant chemotherapy)
  • Have previously received pralatrexate
  • Have received more than the allowed maximum total dose of anthracycline
  • Prior radiation therapy on more than 30% of bone marrow reserve or prior bone marrow/stem cell transplantation
  • Congestive heart failure Class III/IV
  • Uncontrolled hypertension (high blood pressure)
  • Active infection or any serious medical condition, which would impair the ability of the patient to receive protocol treatment
  • Females who are pregnant or breastfeeding
  • Major surgery within 14 days of enrollment
  • Another active cancer in addition to advanced or metastatic breast cancer, except well treated in situ cervical cancer and basal cell skin cancer
  • Dementia or other altered mental status that would prevent the patient from understanding and giving or limit her ability to follow the study requirements
  • Patients who are (HIV)-positive and have a of less than 100 mm3 or detectable viral load within past 3 months and is receiving anti-retroviral therapy
  • Patients with virus (HBV) or virus (HCV) who have a detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)

    Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

    Drug: Pralatrexate Injection · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, Pralatrexate, PDX, (RS)-10-propargyl-10-deazaaminopterin

  • Dietary supplementVitamin B12

    1 mg intramuscular injection Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate.

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    1.0-1.25 mg orally Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate.

    Also known as: Vitamin B9, Folate, Folacin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.

Secondary outcomes

  1. Duration of Response (DOR)

    One patient has a PR as response and duration of response was provided for that patient.

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.

  2. Overall Survival (OS)

    Number of days from first dose of pralatrexate to death.

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but at least every 4 weeks and no more than every 12 weeks (+/- 1 week) if treatment has ended. OS will be collected for up to 2 years from start of pralatrexate.

  3. Incidence of Adverse Events (AEs) and Laboratory Abnormalities

    Time frame: Recorded at all study visits: every 2 weeks while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).

07

Results

Posted Jun 5, 2014
Limitations and caveats
Sufficient patients were enrolled.

Participant flow

Patients were enrolled between 05 Oct 2009 and 10 May 2011. Patients were enrolled in Hungary, France, and the Czech Republic.

Participant flow — Overall Study
MilestonePralatrexate
Started22
Completed0
Not completed22

Outcome measures

PrimaryObjective Response Rate (ORR)

Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.
Reported as:
Number · participants
Objective Response Rate (ORR)
participantsPralatrexate
Objective Response Rate (ORR)1 (0.1 to 22.8)
SecondaryDuration of Response (DOR)

One patient has a PR as response and duration of response was provided for that patient.

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended.
Reported as:
Number · days
Duration of Response (DOR)
daysPralatrexate
Duration of Response (DOR)112
SecondaryOverall Survival (OS)

Number of days from first dose of pralatrexate to death.

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but at least every 4 weeks and no more than every 12 weeks (+/- 1 week) if treatment has ended. OS will be collected for up to 2 years from start of pralatrexate.
Reported as:
Median · months
Overall Survival (OS)
monthsPralatrexate
Overall Survival (OS)11.3 (6.8 to 13.9)
SecondaryIncidence of Adverse Events (AEs) and Laboratory Abnormalities
Time frame:
Recorded at all study visits: every 2 weeks while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).
Reported as:
Number · participants
Incidence of Adverse Events (AEs) and Laboratory Abnormalities
participantsPralatrexate
Incidence of Adverse Events (AEs) and Laboratory Abnormalities21

Adverse events

Collected over All treated patients will be followed for safety through 35 (± 5) days after their last dose or until all treatment-related AEs have resolved or returned to baseline/Grade 1, whichever is longer. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pralatrexate—6/22 (27.3%)1/22 (4.5%)
Most frequent serious events
Most frequent serious events
EventPralatrexate
MUCOSAL INFLAMMATIONGastrointestinal disorders2/22
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders2/22
THROMBOCYTOPENIABlood and lymphatic system disorders2/22
Most frequent other events
Most frequent other events
EventPralatrexate
ANAEMIABlood and lymphatic system disorders1/22
DYSPNOEARespiratory, thoracic and mediastinal disorders1/22
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/22
PYREXIAGeneral disorders1/22

Baseline characteristics

Patients enrolled and treated with study drug.

Age, Continuous
Age, Continuous(years)Pralatrexate
Mean56.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Pralatrexate
Female22
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pralatrexate
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White21
More than one race0
Unknown or Not Reported1
08

Study locations

14 sites
  • Providence Cancer Center
    Portland, Oregon 97213, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • Fakultní nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Multiscan, s.r.o.
    Pardubice, 532 03, Czechia
  • Fakultní nemocnice Královské Vinohrady - FNKV
    Praha, 100 34, Czechia
  • Centre Lutte Contre le Cancer Val d'Aurelle (CRLC)
    Montpellier, Cedex 5 34298, France
  • Centre Régional de Lutte Contre le Cancer Alexis Vautrin
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
  • Centre Georges François Leclerc
    Dijon Cedex, 21079, France
  • Centre Léon Bérard
    Lyon Cedex, 69373, France
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Institut Jean-Godinot
    Reims Cedex 09, 51056, France
  • University of Debrecen Medical and Health Science Center
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Semmelweis University Budapest
    Budapest, H-1082, Hungary
  • National Health Centre of Hungary
    Budapest, H-1145, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 7, 2010
Start
Mar 2010
Primary completionActual
Apr 2012
CompletionActual
Jul 2012
Results first posted
Jun 5, 2014
Last update
Jan 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118624
Responsible party
Sponsor
First posted
May 7, 2010
Start date
Mar 2010
Primary completion
Apr 2012
Completion
Jul 2012
Results posted
Jun 5, 2014
Last update
Jan 7, 2020

Study contacts

Garry Weems, PharmD
study director · Spectrum Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion